TheraRadar
← Back
Data updated: Nov 8, 2026

INCYTE CORP

Specialty
OncologyDermatologyImmunology Execution: Fair

INCYTE CORP is a specialty pharmaceutical company focused on Oncology, Dermatology, Immunology. Key products include ZYNYZ.

2011
Since
6
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
4 Small Molecules 2 Biologics

FDA Novel Drug Designations

(2020-2024)
3 Novel 1 First-in-Class 3 Orphan 1 Breakthrough 2 Accelerated 3 Priority Review 2 Fast Track
See 3 novel approvals →
2024 NIKTIMVO (axatilimab-csfr) First-in-Class · Orphan · Priority Review · Fast Track
2023 ZYNYZ (RETIFANLIMAB-DLWR) Orphan · Priority Review · Accelerated · Fast Track
2020 PEMAZYRE (PEMIGATINIB) Orphan · Breakthrough · Priority Review · Accelerated

INCYTE CORP at a Glance

  • Fast trial execution (32 months median completion)

INCYTE CORP's Recent FDA Approvals

INCYTE CORP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

JAKAFI XR NDA
2026-05-01
ruxolitinib phosphate

INCYTE CORP's Therapeutic Areas

INCYTE CORP's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Dermatology, across 2 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 75%
2 drugs Phase 3: 23 Phase 2: 44 Phase 1: 64
Dermatology 16%
1 drugs Phase 3: 8 Phase 2: 6 Phase 1: 4
Immunology 5%
0 drugs Phase 3: 1 Phase 2: 7
Gastroenterology 3%
0 drugs Phase 2: 1 Phase 1: 8
Metabolic 1%
0 drugs Phase 2: 2

INCYTE CORP's Top Competitors

INCYTE CORP's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Eli Lilly, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology, Metabolic
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Dermatology
Pfizer big-pharma
Oncology, Immunology, Dermatology
Takeda big-pharma
Immunology, Metabolic, Gastroenterology, Oncology
PF PRISM CV big-pharma
Oncology, Immunology, Gastroenterology, Dermatology

INCYTE CORP Pipeline Snapshot

INCYTE CORP has 168 active clinical programs from ClinicalTrials.gov — 32 Phase 3, 60 Phase 2 and 76 Phase 1.

32
Phase 3
60
Phase 2
76
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2026
Povorcitinib
Hidradenitis Suppurativa (HS)
Estimated · aging NCT06212999
Q2 2027
Ruxolitinib Cream
NonSegmental Vitiligo
Estimated · aging NCT06804811
Q3 2027
INCA034176
Chronic Graft-versus-host-disease
Estimated · aging NCT06585774
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • JAKAFI leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 23/58 completed
  • • Speed: 32 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges